Results 381 to 390 of about 369,868 (397)

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

Lancet, The, 2008
Paul Emery, Patrick Durez
exaly  

METHOTREXATE IMPURITIES

The Lancet, 1970
G, Tisman, W A, Winsten
openaire   +2 more sources

Concomitant use of low‐dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis

Pharmacoepidemiology and Drug Safety, 2018
H. Svanström, Marie Lund, M. Melbye, B. Pasternak   +3 more
semanticscholar   +1 more source

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Lancet, The, 2009
Andrés José Maria Ferreri, Reni Michele, Alberto Fabbri   +2 more
exaly  

Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis

Clinical Rheumatology, 2017
J. Rojas-Serrano, Denisse Herrera-Bringas, D. I. Pérez-Román, Renzo Pérez-Dórame, H. Mateos-Toledo, M. Mejía   +5 more
semanticscholar   +1 more source

Emerging nanomaterials with advanced drug delivery functions; focused on methotrexate delivery

Coordination Chemistry Reviews, 2018
Goeun Choi, Tae-Hyun Kim, Jae-Min Oh
exaly  

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

Lancet, The, 2002
Hyon K Choi, Miguel Hernán, James M Robins   +2 more
exaly  

VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Arthritis & Rheumatology, 2016
M. Genovese, R. V. van Vollenhoven, C. Pacheco-Tena, Yanqiong Zhang, N. Kinnman   +4 more
semanticscholar   +1 more source

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Lancet Oncology, The, 2015
Jean-Pascal H Machiels, Robert I Haddad, Lisa F Licitra   +2 more
exaly  

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Lancet Haematology,the, 2016
Andrés José Maria Ferreri, Kate Cwynarski, Maurilio Ponzoni   +2 more
exaly